StockData

Spyre Therapeutics, Inc. (SYRE) company profile

SYRENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$101.46+7.65 (+8.15%)

Close on Nov 18, 2026Market cap $8.95BP/E –Yield –

About Spyre Therapeutics

Pharmaceutical Preparations, SIC 2834

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company that creates long-acting monoclonal antibodies and combination therapies to treat inflammatory bowel disease and rheumatic conditions. Its drug development pipeline targets biological pathways including α4β7, TL1A, and IL-23, which are being advanced as individual therapies as well as fixed-dose pairwise combinations. The company focuses on conditions such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis. Because its product candidates remain in clinical evaluation, Spyre does not currently sell commercial products, though its prospective end-users are individuals suffering from these chronic immune-mediated disorders.

The company operates with 102 full-time employees and does not own or run its own manufacturing, testing, storage, or distribution facilities. Instead, it relies entirely on third-party contract facilities and external service providers across the United States and internationally, including China, while establishing additional domestic supplier redundancies. The provided text details operations across these clinical and manufacturing partners, but it does not specify the location of the company's corporate headquarters.

Summary of the business section of Spyre Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Spyre Therapeutics, Inc.
Founded
2013
Headquarters
Waltham, MA
Address
221 Crescent Street, Building 23, Suite 105 02453
Phone
(617) 651-5940
Employees
102, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, San Diego, California

Stock & identifiers

Ticker
SYRE
Former tickers
AGLE until Nov 28, 2023
Exchange
Nasdaq
IPO date
Apr 7, 2016
Shares outstanding
88M, Jul 28, 2026
Public float
$1.10B, Jun 30, 2025
Filer category
Large accelerated filer
Stock splits
1-for-25 reverse, Sep 8, 2023
SEC CIK
1636282
CUSIP
00773J202
ISIN
US00773J2024
FIGI
BBG0067L94B2
Share class FIGI
BBG0067L94C1
LEI
52990017AIJPRH3HQH40
EIN
46-4312787

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Cameron TurtleChief Executive Officer, Director537,540
Scott L. BurrowsChief Financial Officer79,762
Heidy King-JonesSee Remarks2,845
Sheldon SloanChief Medical Officer8,334
Jeffrey W. AlbersDirector9,360
Michael Thomas HendersonDirector68,606
Healthcare Fund II L.P. FairmountDirector1,190,497
Tomas KiselakDirector9,460,540
Funds Management LLC FairmountDirector812,076
Peter Evan HarwinDirector4,830,177
Mark C. McKennaDirector–
Laurie StelzerDirector–
Sandra MilliganDirector–

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.71M$13.87M$2.20M$17$125
FY2024$6.96M$14.29M$5.80M$12$93
FY2023
Cameron Turtle
$15.92M$48.71M$7.07M$11$94
FY2023
Jeffrey M.Goldberg
$830.21K$122.21K$7.07M$11$94
FY2023
Jonathan Alspaugh
$8.36M$13.59M$7.07M$11$94
FY2022$2.39M$431.09K$1.05M$6$90

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Cameron Turtle
Chief Executive Officer
$665.00K$5.55M$475.48K$14.00K$6.71M-4%
Scott Burrows
Chief Financial Officer
$490.00K$1.43M$254.80K$14.00K$2.19M-1%
Sheldon Sloan
Chief Medical Officer
$503.00K$1.43M$261.56K$14.00K$2.21M-76%
Heidy King-Jones
Chief Legal Officer and Corporate Secretary
$490.00K$1.43M$254.80K$14.00K$2.19M+7%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Apr 7, 2016
Offer price
$10.00
Securities offered
5,000,000
Gross proceeds
$50.00M
Exchange
Nasdaq
First trading day
Apr 7, 2016
First-day close
$9.77-2.3%
Lock-up ends (est.)
Oct 4, 2016

“We have been approved to list our common stock on The NASDAQ Global Market under the symbol “AGLE.” The public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 102 employees, all of whom were employed full time.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?